vs

Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and WORTHINGTON ENTERPRISES, INC. (WOR). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $327.5M, roughly 1.5× WORTHINGTON ENTERPRISES, INC.). WORTHINGTON ENTERPRISES, INC. runs the higher net margin — 8.3% vs 6.8%, a 1.5% gap on every dollar of revenue. On growth, WORTHINGTON ENTERPRISES, INC. posted the faster year-over-year revenue change (19.5% vs -1.7%).

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

Worthington Enterprises, Inc. is an American industrial manufacturing company headquartered in Columbus, Ohio. The company is composed of two business segments, consumer products and building products. Within these segments, the company designs and manufactures pressure vessels such as propane, oxygen and helium tanks, refrigerant and industrial cylinders, camping and residential use cylinders, water system tanks for storage, treatment, heating, expansion and flow control, as well as a variet...

MD vs WOR — Head-to-Head

Bigger by revenue
MD
MD
1.5× larger
MD
$493.8M
$327.5M
WOR
Growing faster (revenue YoY)
WOR
WOR
+21.2% gap
WOR
19.5%
-1.7%
MD
Higher net margin
WOR
WOR
1.5% more per $
WOR
8.3%
6.8%
MD

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
MD
MD
WOR
WOR
Revenue
$493.8M
$327.5M
Net Profit
$33.7M
$27.3M
Gross Margin
25.8%
Operating Margin
9.9%
3.7%
Net Margin
6.8%
8.3%
Revenue YoY
-1.7%
19.5%
Net Profit YoY
10.5%
-3.3%
EPS (diluted)
$0.40
$0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MD
MD
WOR
WOR
Q4 25
$493.8M
$327.5M
Q3 25
$492.9M
$303.7M
Q2 25
$468.8M
Q1 25
$458.4M
Q4 24
$502.4M
Q3 24
$511.2M
Q2 24
$504.3M
Q1 24
$495.1M
Net Profit
MD
MD
WOR
WOR
Q4 25
$33.7M
$27.3M
Q3 25
$71.7M
$35.1M
Q2 25
$39.3M
Q1 25
$20.7M
Q4 24
$30.5M
Q3 24
$19.4M
Q2 24
$-153.0M
Q1 24
$4.0M
Gross Margin
MD
MD
WOR
WOR
Q4 25
25.8%
Q3 25
27.1%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
MD
MD
WOR
WOR
Q4 25
9.9%
3.7%
Q3 25
13.8%
3.0%
Q2 25
12.8%
Q1 25
7.0%
Q4 24
7.8%
Q3 24
6.6%
Q2 24
-31.3%
Q1 24
3.2%
Net Margin
MD
MD
WOR
WOR
Q4 25
6.8%
8.3%
Q3 25
14.5%
11.6%
Q2 25
8.4%
Q1 25
4.5%
Q4 24
6.1%
Q3 24
3.8%
Q2 24
-30.3%
Q1 24
0.8%
EPS (diluted)
MD
MD
WOR
WOR
Q4 25
$0.40
$0.55
Q3 25
$0.84
$0.70
Q2 25
$0.46
Q1 25
$0.24
Q4 24
$0.37
Q3 24
$0.23
Q2 24
$-1.84
Q1 24
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MD
MD
WOR
WOR
Cash + ST InvestmentsLiquidity on hand
$375.2M
$180.3M
Total DebtLower is stronger
$570.5M
Stockholders' EquityBook value
$865.9M
$962.6M
Total Assets
$2.2B
$1.8B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MD
MD
WOR
WOR
Q4 25
$375.2M
$180.3M
Q3 25
$340.1M
$167.1M
Q2 25
$224.7M
Q1 25
$99.0M
Q4 24
$229.9M
Q3 24
$103.8M
Q2 24
$19.4M
Q1 24
$8.0M
Total Debt
MD
MD
WOR
WOR
Q4 25
$570.5M
Q3 25
$577.2M
Q2 25
$583.9M
Q1 25
$590.5M
Q4 24
$597.1M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MD
MD
WOR
WOR
Q4 25
$865.9M
$962.6M
Q3 25
$890.7M
$959.1M
Q2 25
$833.8M
Q1 25
$789.2M
Q4 24
$764.9M
Q3 24
$732.5M
Q2 24
$706.5M
Q1 24
$856.2M
Total Assets
MD
MD
WOR
WOR
Q4 25
$2.2B
$1.8B
Q3 25
$2.2B
$1.7B
Q2 25
$2.1B
Q1 25
$2.0B
Q4 24
$2.2B
Q3 24
$2.1B
Q2 24
$2.0B
Q1 24
$2.2B
Debt / Equity
MD
MD
WOR
WOR
Q4 25
0.66×
Q3 25
0.65×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MD
MD
WOR
WOR
Operating Cash FlowLast quarter
$114.1M
$51.5M
Free Cash FlowOCF − Capex
$39.1M
FCF MarginFCF / Revenue
11.9%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
3.39×
1.89×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MD
MD
WOR
WOR
Q4 25
$114.1M
$51.5M
Q3 25
$137.3M
$41.1M
Q2 25
$137.2M
Q1 25
$-117.5M
Q4 24
$133.0M
Q3 24
$91.8M
Q2 24
$107.0M
Q1 24
$-125.2M
Free Cash Flow
MD
MD
WOR
WOR
Q4 25
$39.1M
Q3 25
$27.9M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
MD
MD
WOR
WOR
Q4 25
11.9%
Q3 25
9.2%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
MD
MD
WOR
WOR
Q4 25
3.8%
Q3 25
4.3%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
MD
MD
WOR
WOR
Q4 25
3.39×
1.89×
Q3 25
1.91×
1.17×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
4.72×
Q2 24
Q1 24
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

WOR
WOR

Building Products$207.5M63%
Equity Method Investment Nonconsolidated Investee Other$120.7M37%

Related Comparisons